LubioScience partners with Cayman Chemical to expand research tools for Swiss scientists

Wednesday, January 22, 2025 @ 12:00 am

LubioScience GmbH, Switzerland’s largest R&D reagent platform, got into a new partnership with Cayman Chemical, a global leader in biochemicals, assay kits, and lipid research tools. This partnership brings Cayman's innovative products and expert services to the Swiss research community, supporting advancements in cancer, neuroscience, metabolism, drug discovery, and more.

Cayman Chemical, headquartered in Ann Arbor, Michigan, has earned a reputation for delivering high-purity reagents, lipids, and assay kits that meet the stringent needs of modern research. Their expertise extends to biochemicals, lipid nanoparticles, and comprehensive assay solutions, all designed to simplify workflows and accelerate discovery. With this partnership, Swiss researchers will benefit from streamlined access to Cayman's high-quality resources, supporting a wide range of scientific pursuits.

“We are delighted to collaborate with Cayman Chemical to expand access to their exceptional tools and services,” said Dr. Muriel Revol, Managing Director of LubioScience. “This partnership reflects our shared commitment to empowering researchers and advancing scientific innovation in Switzerland.”

LubioScience and Cayman Chemical are united by a shared vision: to simplify complex workflows and provide customized solutions that empower the scientific community. By combining Cayman's industry-leading products with LubioScience's local expertise, this partnership ensures that Swiss researchers have the tools they need to drive innovation and make impactful discoveries.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

CELLnTEC joins EU consortium to develop bioprinted liver constructs

European Union (EU) Horizon Europe and Swiss State Secretariat for Education, Research, and Innovation co-funded NEOLIVER Consortium (total €10M award) is set to develop world’s first autologous bioprinted liver designed for clinical use. Coordinated by University of Utrecht, twelve consortium members will develop technologies to establish an automated manufacturing line, vascularize the biopr
February 10, 2025

BioVersys is now publicly listed on the SIX Swiss Exchange

Today, BioVersys (Ticker “BIOV”), a leading Swiss biotech company specializing in novel antibacterial products for serious life-threatening infections, listed its shares at SIX Swiss Exchange. At an opening price of CHF 36.50 per share, the resulting market capitalization of BioVersys was around CHF 216 million.
February 7, 2025

Solvias opens center for biologics, cell & gene therapy in North Carolina

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today the opening of its cutting-edge Center of Excellence for Biologics and Cell and Gene Therapy in the heart of Research Triangle Park (RTP), North Carolina. The new facility expands Solvias’ global network of centers and reinforces its commitment to advancing transformative therapies for cancer and
January 27, 2025

Altamira Therapeutics: Collaboration on radiopharmaceutical targeting strategies

Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have option to negotiate licensing and supply agreement
January 22, 2025

Ymmunobio and PSI win Innosuisse grant for treatment and diagnostic of solid tumors with radio pharmaceutical

Ymmunobio and the Paul Scherrer Institute win Innosuisse innovation grant to develop a radio pharmaceutical with YB’s proprietary YB-800
January 20, 2025